2023-03-31-accounts

Endometriosis UK Annual Report for year ended 31 March 2023

Endometriosis UK

Annual report and financial statements for the year ended 31 March 2023

Company no. 2912853

Charity no. 1035810 OSCR no. SC051651

1

Endometriosis UK Annual Report for year ended 31 March 2023

Contents

For the year ended 31 March 2023

This Trustee and Directors’ report provides an overview of performance in relation to our key objectives and of future plans. It includes key performance data and the stories of some of those Endometriosis UK has helped, in addition to financial summaries and analysis.

Endometriosis UK has helped, in addition to financial summaries and analysis.
	Page
Reference and administrative information	3
Trustees’ annual report	5
Independent auditor’s report	25
Statement of financial activities (incorporating an income and expenditure account)	30
Balance sheet	31
Statement of cash flows	32
Notes to the Financial Statements	33

2

Endometriosis UK Annual Report for year ended 31 March 2023

Reference and administrative information

For the year ended 31 March 2023

Endometriosis UK is a company limited by guarantee and a registered charity.

Company number 2912853 Country of incorporation United Kingdom Country of registration England & Wales Charity Number 1035810 Country of registration Scotland Charity Number SC051651

Registered office and operational address 10 – 18 Union Street, London SE1 1SZ

Trustees Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows: Liz Campbell Chair Tracey Hammonds Treasurer Sanchia Alasia Sarah Atkinson Anna Cooper Andy Glyde Andrew Horne Sera Miller Dr Veena Rao Cassia Rowland Arvind Vashisht

Endometriosis UK has a skills-based Board of Trustees and Trustees are recruited in order to ensure that the board has the right mix of skills and knowledge to provide effective governance. The Board of Trustees has a range of skills and experience including voluntary sector management, fundraising, financial management, primary and secondary health care and of living with endometriosis. Trustees are appointed for a term of three years which is renewable once. Trustees may serve a maximum of six years on the Board.

Company Secretary Emma Cox, CEO Endometriosis UK Key management personnel Emma Cox Bankers CAF Bank Limited PO Box 289 Kings Hill West Malling Kent ME19 4TA Solicitors BDB Pitmans LLP One Bartholomew Close London EC1A 7BL

3

Endometriosis UK Annual Report for year ended 31 March 2023

Auditor

Sayer Vincent LLP Chartered Accountants and Statutory Auditor Invicta House 108-114 Golden Lane London EC1Y 0TL

Medical Advisory Panel

Kirana Arambage, Consultant Gynaecologist, John Radcliffe Hospital, Oxford

Professor Christian Becker, Senior Clinical Research Fellow, John Radcliffe Hospital, Oxford

Liz Bruen, Endometriosis Specialist Nurse, Cardiff and Vale University Health Board

Professor Andrew Horne, Professor of Gynaecology and Reproductive Sciences, Edinburgh University

Shaheen Khazali, Consultant Gynaecologist and Endopelvic surgeon, HCA The Lister Hospital, Chelsea

Dr Uma Marthi, General Practitioner with special interest in women’s health, Rochdale

Dr Veena Rao, General Practitioner with special interest in women’s health, Cumbria

Fevzi Shakir, Consultant Gynaecologist, Royal Free Hospital

Claudia Tye, Endometriosis Specialist Nurse, Guys and St Thomas

Arvind Vashisht, Consultant Gynaecologist, University College London Hospital

Dr Katy Vincent, Associate Professor, Senior Fellow in Pain in Women, John Radcliffe Hospital, Oxford

Our Medical Advisory Panel provides expert advice and guidance on all our work relating to medical information. A very big thank you for their hard work and dedication in supporting the endometriosis community.

The Trustees present their report and the audited financial statements for the year ended 31 March 2023.

Reference and administrative information set out on pages 3 and 4 forms part of this report. The financial statements comply with current statutory requirements, the memorandum and articles of association, the requirements of a directors’ report as required under company law, and the Statement of Recommended Practice – Accounting and Reporting by Charities: SORP applicable to charities preparing their accounts in accordance with FRS102.

4

Endometriosis UK Annual Report for year ended 31 March 2023

About endometriosis

Endometriosis is a disease where cells similar to those lining the womb (the endometrium) grow in other areas of the body, most commonly within the pelvic cavity. These cells respond to the hormonal menstrual cycle in a similar way as the lining of the womb, but unlike the lining of the womb there is no way for it to exit the body. It can cause inflammation, pain and scar tissue (adhesions). Whilst often referred to as a gynaecological condition and relating to the hormonal menstrual cycle, endometriosis can be found outside the pelvic cavity. Limited research means little is known about extra-pelvic endometriosis, it’s thought to affect less than 12% of those with endometriosis, and is most commonly found on the diaphragm or in the thoracic cavity (the chest and lungs).

An estimated 1.5 million women and those assigned female at birth in the UK have endometriosis - that’s 1 in 10 from puberty to menopause who suffer from this disease, although the impact may be felt for life. Whilst for some symptoms are mild, for other it can be severely disabling. We currently do not know what causes the disease and there is no cure.

Endometriosis can result in inflammation, scar tissue, severe pain, painful sexual intercourse, bowel digestive, bladder problems, difficulty getting pregnant, fatigue and a range of other issues. Symptoms vary depending on where the endometriosis is growing and are not exclusive to endometriosis. Diagnosis can take a long time often with multiple visits to healthcare practitioners before symptoms are recognised. All too frequently the severe pain and symptoms are normalised, and those with endometriosis left in the dark about their condition and without access to treatments. Endometriosis UK's own patient surveys have found that on average it takes 8 years from first symptoms to being diagnosed (March 2020). This figure has not changed in a decade and is still unacceptably long. There is a general lack of awareness about endometriosis: a survey we undertook in 2023 highlighted that just 49% of the public are aware that endometriosis is a gynaecological health condition – a figure which drops to just 31% of men.

Currently surgery with biopsy is the only way of diagnosing it definitively, although there are advances in medical imaging (ultrasound and MRI) that enable skilled and trained healthcare practitioners to identify potential endometriosis – however a negative scan does not rule out endometriosis.

There is no wholly satisfactory drug therapy and often the treatment is surgery, although for many this has to be repeated. The repercussions of endometriosis may be enormous: it can affect every aspect of life, from work and relationships to ability to conceive and overall quality of life. Since the condition is hard to see and can take a long time to diagnose, it can feel very isolating - coping with persistent pain, infertility, and other unpleasant symptoms, which are often not believed by others, can also lead to depression.

Endometriosis can also impact partners, family members and personal relationships, and all those affected may need support. This is evident from the number of partners and family members who contact the charity. Although in the past it was considered a disease of the over 30’s, increasing numbers are reporting that they are experiencing troublesome symptoms as early as puberty. There is no evidence to suggest that this is due to an increase in occurrence of endometriosis, but rather is due to the realisation at an earlier age that severe period pain is not normal. Hence help is being sought at an earlier age - something for which the charity's campaigns over many years should take credit. However, without improved diagnosis and treatment the negative outcomes of persistent pain, debilitating symptoms and potential infertility still remain.

5

Endometriosis UK Annual Report for year ended 31 March 2023

Foreword

Over the last 41 years, Endometriosis UK has been at the forefront of demanding and achieving change for the 1.5 million women and those assigned female at birth with endometriosis in the UK, as well as providing vital support and information when people need us most. This year has been no exception, and we’re proud to share with you what has been achieved this year thanks to the incredible support of our volunteers, medical advisors, fundraisers, partners, staff and supporters.

We’d also like to take this opportunity to remember and pay tribute to two endometriosis pioneers who sadly died last year. Author Dame Hilary Mantel passed away in September 2022. Dame Hilary Mantel paved the way for breaking down taboos in talking about endometriosis and its impact, and no doubt inspired the next generation to share their experience and seek support. We also pay tribute to the late Ailsa Irving, the founder of the National Endometriosis Society, now Endometriosis UK, who sadly died in November 2022. Ailsa’s passion and determination to bring together those who suffered with endometriosis and break the silence for those living with the disease were the foundations for our charity, and helped others to be more open and seek the support they deserve.

It is thanks to Ailsa’s and Hilary’s determination that Endometriosis UK and awareness is what it is today.

This year, we’ve continued to witness the long-term repercussions of covid-19, which remain entrenched within endometriosis services. An Endometriosis UK survey in 2022 found that 22% of those with endometriosis who had gynaecology appointments cancelled or postponed during the pandemic were still waiting as of August 2022. This follows gynaecology waiting lists seeing the biggest percentage increase of all NHS specialities during the pandemic and waiting times soaring by 60% across the UK. Far too many with endometriosis are stuck on long waiting lists for appointments, surgery and treatment, often left in debilitating pain. There are also stark inequalities faced by those from marginalised communities in accessing care, which everyone at Endometriosis UK is determined to turn around. Over the last year, we’ve worked with those from marginalised communities to understand the additional barriers faced in accessing care, and how we can tackle these.

Our range of support services enable us to reach marginalised communities and provide a wide range of ways for the community to engage with our work. The pandemic exposed the challenges faced by those with endometriosis and the importance of our work to provide a beacon of support and hope to anyone affected by the disease. We have continued to recruit and train incredible volunteers, who generously give their time despite their own experiences of living with endometriosis, with 60 new volunteers trained across the year, increasing our total number of active volunteers to 201. We’ve run a series of successful webinars on a variety of topics including endometriosis and sex, getting the most out of a GP appointment and managing pain.

In 2022/23 we expanded and added resource into our information delivery. With the appointment of a Specialist Advisor in April 2022 and a Head of Information and Support in September 2022 we have developed a robust and sustainable way of producing new and relevant information on endometriosis. Last year we ran a systematic review of all our information materials to ensure they were up to date and in line with current clinical practice. In addition, we have updated our key information resources including diagnosis, medical treatments, surgery for endometriosis, and bladder endometriosis. We will continue to expand our information provision in 2023/24.

We’ve continued to raise the voices and experiences of the endometriosis community with decision makers across all four nations of the UK. A breakthrough moment was after a campaign led by Endometriosis UK, NICE (the National Institute of Health and Care Excellence) agreed to review parts of the NICE Guideline on Endometriosis Diagnosis and Management, and appointed Emma Cox, our CEO, to the NICE Committee that will undertake the review.

Whilst the guideline sets the baseline for endometriosis care in the NHS, there are gaps which mean a lack of support and access to care.

6

Endometriosis UK Annual Report for year ended 31 March 2023

Over the next year, we will continue to campaign for change so everyone with endometriosis has a prompt diagnosis and high-quality care, and funding for more research to improve care options. This includes campaigning for NHS’s across the UK to implement the NICE guideline, ending the postcode lottery of treatment and care, providing a baseline across the UK.

Thank you to our incredible fundraisers who have taken part in an amazing array of challenges over the last 12 months – from sky dives and ultra-ultra marathons to tea parties and wearing yellow in the workplace. All money raised goes towards helping us continue to be there for and raise the voices of everyone affected by endometriosis, and our work would not be possible without your generosity.

It is vital that employers provide support for employees with Endometriosis in the workplace and are aware of the impact it can have on an individuals’ work life. Our Endometriosis Friendly Employer Scheme has continued to grow, with a total of 104 employers signed up to the Scheme. Through the scheme, these workplaces are taking action to ensure employees with endometriosis and menstrual health conditions are supported and enabled to thrive at work. We were delighted the Welsh Government, Bank of Ireland, Royal College of Obstetricians and Gynaecologists, and several NHS trusts signed up to the scheme in 2022.

We’d like to end our introduction by thanking our incredible supporters for what you’ve helped us achieve this year. With new research on the horizon and a strategy in place that aims to deliver real change, we hope you’ll stand with us during the year ahead.

Liz Campbell (Chair)

Emma Cox (CEO)

7

Endometriosis UK Annual Report for year ended 31 March 2023

Objectives and activities

Purposes and aims

The aim of the annual report is to review the charity’s aims, objectives and activities each year, and share with our supporters what you have helped us achieve. We’re incredibly proud of everything we have achieved but know there is much more to do.

The trustees report the success of each key activity and the benefits the charity has brought to those groups of people that it is set up to help. The review also helps the trustees ensure the charity's aims, objectives and activities remained focused on its stated purposes.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set.

Achievements and performance

The charity's key activities and who it tries to help are described below. All its charitable activities are undertaken to further Endometriosis UK’s charitable purposes for the public benefit, and focus on:

• Support for everyone living with endometriosis

• Information and supporting research

• Raising awareness and campaigning

• Resourcing the organisation so that we can deliver more

The following outcomes for the next 5 years have been agreed:

• Reducing diagnosis time

• Improving access to high quality treatment

• Ensuring everyone with endometriosis has the support they need

8

Endometriosis UK Annual Report for year ended 31 March 2023

Key achievements

The continued impact of the covid pandemic on NHS services, along with inflation and the cost of living challenges, have impacted significantly on many in the endometriosis community and the charity. Despite this, we achieved several long-term objectives, focused on supporting those with endometriosis, reducing diagnosis times, and campaigning to improve access to treatments. We have highlighted a few of these below, with more details of our activities on following pages.

Support for people living with endometriosis

Offering support for those living with endometriosis is at the heart of everything we do. We continue to be there for people with endometriosis, with the support of our fantastic team of trained volunteers providing direct support through our growing community of Support Groups, Helpline and Webchat services, and online Health Unlocked forum. Post-covid we have supported community groups transitioning back to face to face meetings and improve our volunteer training offer to ensure our services meet the needs of the endometriosis community.

Information

Access to accurate information is essential for those with endometriosis. The appointment of our Specialist Advisor gave us additional clinical expertise that allowed us to diversify and improve our information provision in 2022. We strengthened our partnerships with endometriosis specialist centres across the UK and increased our digital information provision offer delivering more webinars than ever before.

Research

We know that research is at the core of improving the lives of those with endometriosis. We are involved in a wide range of research activities, aiming to ensure the views of those with endometriosis are always considered in research. We worked with Verity, the PCOS charity, to support a debate in the UK Parliament on increasing research funding for endometriosis and PCOS, as well as being a partner in clinical trials, helping with PPI (public and patient involvement) to ensure input from patients, reviewing patient materials and helping to recruit study participants.

Awareness and Campaigning

Our policy and campaigns work in 2022 continued to raise vital awareness of endometriosis across all 4 nations. Endometriosis UK’s campaigning was instrumental to NICE agreeing to review and update their guidance on endometriosis diagnosis and management, and Emma Cox, our CEO, has also since been appointed to the NICE Guideline Committee reviewing the guidance. It is thanks to our incredible supporters that we are able to make these strides in improving care for all.

We have continued to influence the policy agenda in all 4 nations, including in the development of the Women’s Health Strategy in England, and Women’s Health Action Plans in Scotland and Wales. We’ve been elected as the Secretariat to the Cross Party Group on Women’s Health in Scotland, and continue to provide Secretariat to the APPG on Endometriosis in Westminster.

We’re incredibly grateful to our amazing volunteers and supporters who share their experiences with the media. Despite their own pain and struggles, they use their experience to campaign for change and raise vital awareness with the media. This has seen coverage across all major news outlets including the BBC, ITV, and Channel 5 news.

Resourcing

Our team of 201 trained volunteers deliver our direct support services. We have continued to facilitate virtual training for volunteers, and have continued volunteer recruitment throughout the year.

9

Endometriosis UK Annual Report for year ended 31 March 2023

Our staff team has grown over the last year, with new roles to increase and diversify the work we do, improving capacity and expertise within different project areas. New appointments included our first post in Scotland, a Scottish Development Coordinator, enabling us to better support volunteers and lead on projects throughout Scotland; plus a Specialist Advisor (part-time), an Endometriosis Specialist Nurse to help develop our information provision and provide clinical expertise to our support volunteers. We continued to develop our diversity and inclusion work, undertaking research and developing our Equality, Diversity and Inclusion (EDI) Strategy. In the year ahead we have appointed an EDI Manager to take this work forward.

We were delighted to receive grants from a number of funders and continue to deliver projects in Scotland, Wales, and England, including the Health and Social Care Alliance and National Lottery Community Fund, and Department of Health and Social Care. This has helped us provide resources for Support Groups, volunteer training, and deliver vital information and awareness-raising activities. A grant through the Department of Health and Social Care VCSE Health and Wellbeing Fund will enable us to expand employer and employee resources to cover six of the most common menstrual health conditions.

10

Endometriosis UK Annual Report for year ended 31 March 2023

Support for those living with endometriosis

“The lady who I spoke to when I called the helpline will always be a hero to me”

• support services user

Our volunteer-led support services continue to be a core part of how we support the endometriosis community. The cost-of-living crisis have highlighted new challenges in relation to diagnosis times, treatment options, and care which we are working hard to voice and address.

We have been able to substantially increase in our capacity to support those in the endometriosis community through our support services and have trained 60 new volunteers bringing our total number of active volunteers to 201. A warm welcome, and a big thank you to all our volunteers who do so much to support the endometriosis community.

We have continued to diversify support services for those living with endometriosis and provide a more inclusive service. Our hybrid services enable us to improve our reach to marginalised communities and provide service users with a wide range of engagement options to better suit their individual support needs.

Our new Scottish Development Coordinator post has continued developing strong links with the Scottish government and health boards, and to raise awareness of our Endometriosis Friendly Employer (EFE) scheme. We’re looking forward to welcoming our first Welsh Development Coordinator in the year ahead.

During the year, we built on our Equality, Diversity and Inclusion (EDI) work, commissioning research into the lived experience of marginalised communities living with endometriosis. This formed the basis of our new EDI Strategy, aiming to ensure we continue to diversify and improve our organisational practices, support and services to deliver for the whole endometriosis community.

Highlights

• 55 active support groups across the UK, including 6 new support groups set up.

• 318 support group meetings held over the year.

• 11 training sessions for volunteers.

• 4798 new members signed up to our online moderated Health Unlocked forum, taking the total number of members to 64,601.

• 439 calls were answered by our Helpline volunteers.

• 1064 webchat threads.

• 13 webinars led by medical experts, viewed by 3,780.

Future Plans

• Ensuring our support services are sustainable through the recruitment and training of new volunteers.

• Ongoing support of all our volunteers.

• Identify areas for new support groups.

• Increase our helpline opening hours by recruiting more volunteers.

• Continue to build and strengthen our webchat support service.

• Continue to develop a programme of webinars and Living with Endometriosis information events in partnership with BSGE Centres across the UK.

• Continue to work towards Equality, Diversity and Inclusion being central into our work.

11

Endometriosis UK Annual Report for year ended 31 March 2023

What motivates our volunteers

“ Being able to support others, having experienced so much myself and knowing a lot about endo, I feel like I can make a difference ”.

“ Having relied on the groups so much in my early diagnosis I wanted to give back to the community, and I love the people with endo in our area who attend as they are all truly remarkable, resilient and kind ”

“ Helping just one person to research their options and not have to wait 28 years for a diagnosis ”

“ I have endometriosis and understand how lonely and confused newly diagnosed people can feel. Health unlocked is a great way for people to reach out for support and information, and I want to help ”

A big THANK YOU to all our amazing volunteers, we could not run our support services without you, thank you for your time, hard work and dedication!

Feedback about our support services

“ I found it to be a fantastic way to engage with an individual who really understands what it’s like to manage life with Endo ” ( Webchat )

“Thank you the online chat service is so helpful when you have questions and someone who understands and can provide support that may be needed at certain times. Great support from great people. Thank you” (Webchat)

“What a wonderful opportunity to speak with other women, who understand. Thank you for all you do”. ( Support Group)

“The webinar gave some really useful information, both presenters were warm, friendly and informative.”

( Webinar )

12

Endometriosis UK Annual Report for year ended 31 March 2023

Information & research

Highlights

Our Endometriosis Friendly Employer Scheme continued to grow, with 104 active members at the end of March. These workplaces have committed to ensure employees with endometriosis and menstrual health conditions are supported and enabled to thrive at work. We were pleased to see organisations such as the Welsh Government, the Bank of Ireland, the Royal College of Obstetricians and Gynaecologists, and several NHS trusts signing up for the scheme in 2022.

During Endometriosis Action Month in March in particular, we delivered a number of talks for employers, providing information about endometriosis, impact it can have on work life, and how employers can provide support. We hosted an Endometriosis and the Workplace webinar as part of our Workplace Menstrual Wellbeing project, well attended by over 40 organisations. Through the Endometriosis Friendly Employer scheme, organisations have begun to make great progress for employees with endometriosis; by holding events to raise awareness of the disease and the impact it can have, developing guidance and policies to better support those with endometriosis at work, working with Endometriosis UK to deliver training for staff and nominating workplace Endometriosis Champions to increase awareness and signpost.

Behind the scenes, our information was reviewed as part of the regular review process. We worked with a team of MSc students to assess the usability of our website and improvements that could be made and started developing a new site to deliver these.

We are pleased to be involved in a range of research projects. Research into endometriosis is vital to find out more about the disease. Only through research will we find out more about the cause of endometriosis, how to better treat and manage it, the support people might need, and, one day, a cure. We have partnered with university researchers and clinical trials teams to aid recruitment and participation in a number of research projects aimed at improving the lives of those living with endometriosis, including the following clinical trials:

DIAMOND: Deep infiltrating endometriosis: management by medical treatment versus early surgery

ESPriT2: The effectiveness of laparoscopic treatment of isolated superficial peritoneal endometriosis for managing chronic pelvic pain in women: a randomised controlled feasibility trial.

REGAL: Recurrence of Endometriosis: A randomised controlled trial of clinical and cost-effectiveness of Gonadotrophin Releasing Hormone Analogues with add-back hormone replacement therapy versus repeat Laparoscopic surgery

ADVANTAGE – Advanced Discovery of Visceral Analgesics via Neuroimmune Targets and the Genetics of Extreme Human Phenotype - aims to improve how we treat people with visceral pain from a variety of diseases, such as endometriosis; focusing on their pain rather than just their underlying disease.

In November, MPs attended a debate in Westminster Hall on research into endometriosis and polycystic ovary syndrome (PCOS). Working with Verity, the charity for PCOS, our campaigning meant almost 6000 people wrote to their local MPs to ask them to attend, with each of the UK’s 650 MPs being contacted about the issue.

Future plans

• Work with the research community on projects to learn more about endometriosis, its treatment, and management, focussing on the needs of those with the disease.

• Continue to push for increased funding into research.

• Gain accreditation with the Patient Information Forum the quality mark for health information in the UK.

• Continue to develop new and relevant information for the endometriosis community.

• Expand the Endometriosis Friendly Employer scheme.

13

Endometriosis UK Annual Report for year ended 31 March 2023

Awareness and campaigning

Endometriosis UK continues to raise the voices of those affected by endometriosis directly with decision makers across all 4 nations, to raise awareness and drive real change. We work to ensure patient voices are at the heart of our campaigning work, including supporting people to lobby their local politician directly to share their experience and campaign for change. A total of 2147 emails were sent to politicians in 2022-2023.

A success was, due to a campaign led by Endometriosis UK, NICE (the National Institute of Health and Care Excellence) agreed to review parts of the NICE Guideline on Endometriosis Diagnosis and Management, and appointed Emma Cox, our CEO, to be on the NICE Committee that will undertake the review.

Whilst the NICE guideline sets the baseline for endometriosis care in the NHS, there are gaps which mean a lack of support and access to care. We didn’t get all we wanted, which was a full review of the Guideline, and will continue to campaign for this whilst working constructively with NICE on the part review they are undertaking. Over the next year, we will continue to campaign for change so everyone with endometriosis has a prompt diagnosis and high-quality care, and funding for more research to improve care options. This includes campaigning for NHS’s across the UK to implement the NICE guideline, ending the postcode lottery of treatment and care and providing a baseline across the UK.

In Westminster, the long-awaited Women’s Health Strategy was published and we were pleased to see it included commitments Endometriosis UK had requested, including action to improve endometriosis diagnosis and care, as well as increased support for menstrual health research. We continue to lobby the UK Government to ensure the commitments within the Women’s Health Strategy are met and have taken part in numerous roundtable events with Women’s Health Ambassador Professor Lesley Regan and attended a meeting at 10 Downing Street to campaign for change. We also continue to provide Secretariat to the AllParty-Parliamentary Group (APPG) on Endometriosis and work with MPs from across all political parties to raise the voices of the endometriosis community.

In Scotland, we continue to work with the Scottish Government on the implementation of their Women’s Health Plan. We have also taken on the Secretariat to the Cross-Party-Group (CPG) on Women’s Health in Scotland and have expanded our relationships with MSPs and developed links between Government and our Scottish Support Groups to ensure the needs of those in Scotland are understood by Government.

In Wales, we are an active member of a coalition of charities working to implement a Women’s Health Plan for Wales, which we look forward to being launched in the next year. Working in Northern Ireland remains challenging due to the lack of elected government, however we have worked with Northern Ireland MPs in Westminster to raise awareness.

The impact that COVID-19 has had on the NHS continues to have a huge and detrimental impact on endometriosis care, and we continue to work with partners and politicians across all four nations to ensure that those with endometriosis are given due priority and are not left behind.

We were proud to run another successful Endometriosis Action Month in March 2023, with a series of exciting parliamentary and community events in all four nations, as well as raising awareness with the media. Thanks to the generosity and courage of those with endometriosis being willing to share their experience, the media spoke about endometriosis throughout the month including within the Guardian, News Beat, ITV News and BBC News. Our events also saw us engage with politicians across all nations, as well as a weekly Instagram Live and webinar programme.

Highlights:

• A total of 2147 emails were sent to politicians from the endometriosis community using our e-lobbying tool.

• NICE agree to update three parts of the NICE Guideline on Endometriosis Diagnosis and Management, and appointed CEO Emma Cox to the Review Committee.

14

Endometriosis UK Annual Report for year ended 31 March 2023

• We played an instrumental part in developing policy across all 4 nations, including in the development of Women’s Health Strategies and by responding to numerous government consultations.

• Providing Secretariat to the APPG on Endometriosis in Westminster and the CPG on Women’s Health in Scotland.

• Endometriosis in the media: The media continues to raise vital awareness of the media, and the last year has seen coverage across all major broadcast and print outlets including the BBC, ITV News, Channel 5 and the Guardian.

• During Endometriosis Action Month alone, our social media reach increased by 122%, meaning even more people are aware of endometriosis, its impact, and how to seek support.

• We were delighted to launch our TikTok Channel to raise vital awareness of endometriosis and the associated symptoms to reach new and younger audiences.

Future plans:

• Diagnosis: re-running our diagnosis survey to see if diagnosis time has changed since our last survey in 2020 which highlighted it takes a shocking 8 years on average to diagnose endometriosis. Following this, we’ll be campaigning to improve diagnosis times across all 4 nations.

• Waiting times: We will continue to highlight the impact of NHS waiting lists on waiting, and campaign for those with the endometriosis to be given due priority in accessing care.

• Relationships with Government: We will continue to build relationships with Governments to campaign for change, develop policy and raise the profile of endometriosis across all 4 nations.

15

Endometriosis UK Annual Report for year ended 31 March 2023

Resourcing

Highlights

We’ve continued to work to deliver our new 5-year strategic plan, strengthening our ambitions and resolve to ensure everyone living with endometriosis has a prompt diagnosis, high quality care and the support they need.

During the year, we continued to follow government guidance on covid and living with covid, moving from home to hybrid working for those based in London. Our staff team grew further this year, with five new permanent roles, and allowed us to increase the amount of work we can do. As new staff settle in, we look forward to being able to deliver more for the endometriosis community in the year ahead.

Despite the pressures and uncertainty in the external environment post pandemic, inflation, and the cost of living crisis, we had another positive year with fundraising. This is thanks to our incredible community of supporters, funders and partners and continued strategy to diversify our sources of income.

Income

Expenditure

Future plans

• Continue to implement our 5 year strategic plan

• Continued investment in volunteer training, support and development

• Enhance our regular giving and membership offers and grow these

• Develop and grow our partnerships with funding bodies, charitable trusts & companies

• Increase online donations

16

Endometriosis UK Annual Report for year ended 31 March 2023

Supporters

We’re incredibly grateful to our amazing supporters who have taken part in a variety of fundraising challenges, including Walk for Endo and the 1 in 10 challenge. We are also delighted to have offered three new events to our programme of fundraising activities, including Winter Walk for Endo and two non-physical activities – Tea for Endo and Go Yellow! Almost 1000 people signed up to these challenges, including many work-places. Separate to these events over 100 people took on their own challenges and found creative ways to fundraise for our work.

During the year we expanded the range of challenge events on offer to include treks and skydives as well as more running events across the UK, ensuring there’s more opportunities to get involved wherever our supporters live. We were fortunate to secure spaces in two large scale popular events, the London Landmarks Half Marathon and the Great North Run , both of which were a great success and will remain a permanent fixture on our portfolio. We were pleased to be able to cheer on our supporters at challenge events once again, including the Asics 10k, London Landmarks Half Marathon, The Great North Run, Brighton, and London Marathons, and look forward to seeing more of our supporters take on challenges at events in the future. It was great to have such enthusiastic and dedicated cheer squad volunteers at each of these events too.

Future plans

• Increase participation in events and opportunities to engage with and support us

• Deliver a varied and exciting year-round calendar of fundraising events

• Provide the best support to our donors and fundraisers and increase support from individuals

• Work with ne ~~w~~ ambassadors to raise awareness and support

• Secure new corporate partners and relationships with funders

17

Endometriosis UK Annual Report for year ended 31 March 2023

Beneficiaries of our services

Our beneficiaries include all those with or impacted by endometriosis.

Endometriosis UK is committed to supporting and advocating for everyone affected by endometriosis regardless of race, gender, sex, gender identity, class, sexual orientation or disability and ensuring diversity. Everyone affected by endometriosis needs to be acknowledged, and we know that we must do more to identify the needs of all those affected by endometriosis, develop, maintain, and evaluate our work to meet those needs and advocate for necessary change and ensure all voices are heard. We know that there are additional complexities in accessing healthcare and support for those from Black, Asian and minority ethnic communities, and for the LGBTQ+ community.

We are taking steps to actively ensure we drive change for those from under-represented groups. The Board’s Diversity & Inclusion Group continues to take this work forward. Having undertaken training for all our volunteers, Trustees and staff, we commissioned research to ensure we understand the needs of all those with endometriosis including those from under-represented groups. This informed the development our Equality Diversity and Inclusion strategy, to set out our priorities. This strategy is available to read on our website.

Financial review

The Trustee Board oversees the charity’s finances. To support the Board, a Finance Committee meets regularly, chaired by our Treasurer.

For the financial year 2022/23 we planned a significant increase in our expenditure so that we could improve support to the endometriosis community and have a louder voice for the community. Expenditure increased from £580,440 in 2021/2022 to £787,521 in 2022/2023. Planned investment was undertaken as the financial situation over the year became more certain, with expenditure regularly reviewed and carefully monitored. Investments included developing a Workplace Menstrual Wellbeing project and raising funds to increase support and activity in Wales allowing us to recruit our first staff member in Wales in summer 2023. With increasing staff, we slightly expanded our office space within the Royal College of Obstetricians and Gynaecologists building. At the Royal College we are part of a hub for women’s health charities enabling us to work collaboratively more easily with the Royal College and other charities with similar interests. Further expansion of our work is planned over the next year, including development of our information provision, expanding our support network, and increasing our campaigning and awareness work.

Despite the increase in expenditure we generated a surplus of £107,049 due to the amazing fundraising from our supporters and the increased skill of our fundraising staff team.

Income increased again this year from £868,870 in 2021/2022 to £894,970 in 2022/2023. The Trustees aim to secure diverse income streams to ensure our income is sustainable and more resilient to change in the external environment. In this way we can achieve our objectives – we have ambitious plans for a small charity. Through both managing costs and developing our fundraising, the Trustees carefully monitored finances over the year to ensure the year ended with unrestricted reserves that comfortably met our reviewed reserves policy. As part of our planned growth strategy, we have grown our reserves which enabled us to grow the organisation over the last 3 years in a sustainable way. Having reserves enabled us to survive the initial impact of Covid and undertake managed growth through the pandemic and the more recent cost of living crisis. We want to continue to grow so we can do more to support all those with endometriosis.

The Trustees working closely with the CEO will continue to look for opportunities to develop further fundraising opportunities along with how best to spend our income to deliver the most for those with endometriosis.

18

Endometriosis UK Annual Report for year ended 31 March 2023

Principal risks and uncertainties

The charity reviews risk on a regular basis and used a risk based management approach to decision making. This continued in 2022-23, covering the key aspects of our work including finance, governance and management, operational and external factors. Material risks were identified, reviewed and mitigated by the Trustees and this will continue in the year ahead. Time was spent examining strategic risks in the external environment and reviewing the strategic plan against these.

Our risk statement was reviewed, and our risk register updated. The risk register is reviewed on a regular basis by staff and Trustees. Given the uncertainty of the economic situation, a range of 5-year scenarios and financial modelling was undertaken to enable the Trustees to plan how to manage the charity, monitor progress and mitigate risks. Expenditure continues to be carefully monitored given uncertainty about fundraising income in the challenging economic climate.

Our key risks, and our mitigations for these are:

• Not adapting to the changing environment and not meeting the needs of the endometriosis community. We must be a reliable source of valuable information, and proactively campaigning for changes needed to improve the care and treatment, including those currently undiagnosed. Throughout the year we focused on new ways of providing support as the UK moved to ‘living with covid’, planned and launched campaigns to improve access to treatment and care, and worked with healthcare practitioners and partners to provide current information.

• Not having sufficient funds to deliver services and achieve objectives. Without growing our income, it will be more difficult to deliver our ambitious strategy. We are focusing on both improving our stewardship to support individuals that fundraise for us and continuing to diversify our income sources for example through grants and corporate partnerships.

• Information technology – risk our systems fail to meet our operational need. IT systems are crucial to our work, and as a small charity our IT support is via external providers. We reviewed all our providers, identified and implemented new software to support our work, and upgraded our website.

Reserves policy and going concern

Our reserves policy is to hold unrestricted reserves equivalent to at least 6 months’ operating costs. We hold financial reserves for practical reasons, including:

• Ensuring we can go on funding our vital work should our income fall below target. Having reserves should give us time to adjust expenditure without causing undue disruption to our projects and those we support.

• Providing working capital to meet upfront expenditure during the year before income is received.

• To provide resource for investment, eg developing services and ensuring we maximise our reach.

As detailed above our reserves have increased this year which will support the expansion of our work and ensure our sustainable growth. Free reserves as of 31[st] March 2023 were £1,201,605. This equates to 11 months of operating costs for the financial year taking account of designated funds which have been set aside for committed future projects. £97,166 of restricted funds was carried forward. We started the year in a good financial position, having worked hard over prior years to build reserves in order to expand our activities. We have cautiously expanded to ensure sustainability, with expenditure minimised whilst we ascertained the impact of inflation and cost of living challenges. The reserves level achieved is based on meeting our reserves policy over the next two years as the charity grows.

We are delighted with the response to our newer fundraising events over the year including Winter Walk for Endo, Go Yellow and Tea for Endo and would like to thank all of our fundraisers, donors and partners who were so generous over the year.

19

Endometriosis UK Annual Report for year ended 31 March 2023

This has helped us invest in new areas of work to support the endometriosis community, and to plan for further activities and support in the year ahead.

Staff and Trustees reviewed the reserves policy in March 2023 and continue to carefully monitor the cash flow position and reserves using scenario analysis to assess future reserves. Having sufficient reserves allows us to plan for and deliver future projects, with a focus on decreasing diagnosis times, raising awareness and supporting those with endometriosis. It also enables us to leverage further income, for example some funders are happier to part fund activities where the organisation has already raised some money. Having sufficient reserves allows us to make the most of opportunities.

The Trustees have reviewed the level of reserves and available liquid resources in the context of plans over the next 12 months, the five-year financial scenario plans and the organisational risk assessment. The Trustees believe that Endometriosis UK has sufficient financial resources to continue in operational existence for the foreseeable future and that we are well placed to manage its operating risks successfully. They have therefore continued to adopt the going concern basis of accounting in preparing the annual financial statements.

Structure, governance and management

Endometriosis UK is a charitable company limited by guarantee, incorporated on 25th March 1994 and registered with the Charity Commission as a charity on 29th March 1994. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In March 2021, we registered with OSCR- the Scottish Charity Regulator.

The Board of Trustees has 3 sub committees, Finance, Diversity and Inclusion and Nominations. These operate to agreed Terms of Reference and with limited delegated powers from the Board.

During 2022 our governing document, the Articles of Association, were reviewed and updated, with approval at the November 2022 AGM. Two changes were made, firstly that trustees be elected for a term of three years, with a maximum of six years as a trustee; and secondly that those considered Company Members of the charity was changed to be the Trustees.

All Trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 6 to the accounts.

Trustee induction and training

The recruitment of Trustees is framed by an audit of the skills held by the members of the Board. Trustees are appointed by an open recruitment process using both search and advertisement as appropriate, against an agreed person profile and job specification. Shortlisted candidates are interviewed by a Nominations Committee of the Board who make a recommendation to the Board. The AGM of the Charity confirms all appointments.

New Trustees undergo a formal induction process covering, governance, risk management, financial systems and agreed procedures.

The Board hold an annual away day to consider strategy and review the performance of the Board. Diversity and Inclusion training was undertaken by Board members, and opportunities for training and knowledge development are raised with the Board, for example the training offered by our auditors.

With four trustees reaching their six-year term of office in 2023, we will be recruiting new trustees in 2023.

20

Endometriosis UK Annual Report for year ended 31 March 2023

Risk Management

The Trustees have a Risk Policy and a Risk Register. Each Board Meeting assesses whether new risks have emerged or whether any of the identified risks have changed in severity. The whole risk register was reviewed at the September and November Board meetings. Trustees consider that the formulated plans to deal with such risks are appropriate at present.

Statement of responsibilities of the trustees

The trustees (who are also directors of Endometriosis UK for the purposes of company law) are responsible for preparing the trustees’ annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

• Select suitable accounting policies and then apply them consistently

• Observe the methods and principles in the Charities SORP

• Make judgements and estimates that are reasonable and prudent

• State whether applicable UK Accounting Standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements

• Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

• There is no relevant audit information of which the charitable company’s auditor is unaware

• The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. At the November AGM, the members voted to agree proposed changes to the governing document of the charity, the Articles of Association, to change the legal members of the charity to be the Trustees. The trustees have no beneficial interest in the charity.

21

Endometriosis UK Annual Report for year ended 31 March 2023

Auditor

Sayer Vincent LLP was re-appointed as the charitable company's auditor during the year and has expressed its willingness to continue in that capacity.

The Directors annual report has been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

The trustees’ annual report has been approved by the trustees on 11[th] September 2023 and signed on their behalf by

Liz Campbell (Chair)

Tracey Hammonds (Treasurer)

22

Endometriosis UK Annual Report for year ended 31 March 2023

Acknowledgements

We could not do the work we do without the time and knowledge kindly offered to us by our volunteers, fundraisers, speakers, health experts and medical advisors. Without them, we would not be able to reach and support the people we do. We would like to thank them all for their on-going support and generosity.

All those volunteers who have given up their time to support people affected by endometriosis - through the Helpline, Support Groups, Webchat, Health Unlocked - receive a special vote of thanks. A huge thanks as well to everyone who took on a challenge event or hosted their very own fundraising project to raise money to support the charity.

And a very heartfelt thank you to those who told their stories to the media to raise awareness, which can be such a hard and emotional thing to do yet is vital in raising awareness and helping others.

As always, all of our work will be a team effort. Our staff, volunteers, members, trustees, those with endometriosis in our wider community, their friends and family, healthcare professionals, researchers – all of those who work so tirelessly as part of Team Endo are making a huge difference where it is so desperately needed. We are grateful to those organisations who have provided expertise and support to help us raise awareness very generously free of charge, with special thanks to the team at Come the Glorious Day, and to Clear Channel for supplying our first digital billboards.

We are extremely grateful for the continued and new support of the funders below. We would also like to thank every individual and group who has made a donation and encouraged others to support and fundraise for us this year. We would also like to thank our small and dedicated staff team.

or us this year. We would also like to thank our small	and dedicated staff team.
The National Lottery Community Fund	SENSE Foundation
Department of Health and Social Care	Blackbaud
The Health and Social Care Alliance, Scotland	Cecil Pilkington Charitable Trust
Time Of The Month (TOTM)	Pilkington Charities’ Fund
Brown Rudnick LLP	Edith Murphy Foundation
Intuitive Surgical Limited	N. Smith Charitable Settlement
Access Foundation	Fritton Trust

We also received the following payment:

Chugai Pharma Europe Limited: £1,800 - To coordinate the recruitment of patients either directly or via social media to attend group virtual meetings with Chugai to gather information and trial acceptability regarding a Phase II study in endometriosis.

Endometriosis UK is committed to fundraising in an honest and transparent way. All staff, volunteers, contractors and partner organisations fundraising for Endometriosis UK are required to adhere to our high standards of ethical fundraising and comply with the code of the Fundraising Regulator. Our community of hundreds of supporters have generously given and continue to give their time to raise money for the charity. Endometriosis UK also has a commercial participator agreement in place with TOTM, who fundraised through per-product donations during the year.

The charity established commercial participator agreements with all sole traders and businesses known to be fundraising for Endometriosis UK and monitored the activities of those fundraising by reviewing proposed messaging and products, and social media monitoring. There were no known failures to comply with the code of the Fundraising Regulator, and no complaints were received regarding staff, volunteers or individuals fundraising for Endometriosis UK. All staff and volunteers are required to adhere to Endometriosis UK’s safeguarding policy, which aims to protect vulnerable people across all aspects of our work, including fundraising.

23

Endometriosis UK Annual Report for year ended 31 March 2023

About Us

Meet the Endometriosis UK governance and staff team

How to get involved

The more people working together the stronger we are and the louder our voice. We have a range of ways you can get involved, for more information please check out our website: www.endometriosis-uk.org/get-involved.

If you would like to hear what we are up to throughout the year, sign up for our regular e-update.

Contact

Endometriosis UK 10 -18 Union Street, London SE1 1SZ Tel: [phone] Helpline: 0808 808 2227 www.endometriosis-uk.org/contact-us Twitter @EndometriosisUK Instagram endometriosis.uk Facebook www.facebook.com/endometriosis.uk.org

24

Endometriosis UK Independent Auditor’s Report for year ended 31 March 2023

Independent auditor’s report to the members of Endometriosis UK

Opinion

We have audited the financial statements of Endometriosis UK (the ‘charitable company’) for the year ended 31 March 2023 which comprise the statement of financial activities, balance sheet, statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

• Give a true and fair view of the state of the charitable company’s affairs as at 31 March 2023 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended

• Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice

• Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended)

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on Endometriosis UK's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

25

Endometriosis UK Independent Auditor’s Report for year ended 31 March 2023

Other Information

The other information comprises the information included in the trustees’ annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

• The information given in the trustees’ annual report, for the financial year for which the financial statements are prepared is consistent with the financial statements; and

• The trustees’ annual report, has been prepared in accordance with applicable legal requirements

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

• Adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

• The financial statements are not in agreement with the accounting records and returns; or

• Certain disclosures of trustees’ remuneration specified by law are not made; or

• We have not received all the information and explanations we require for our audit; or

• The directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemptions in preparing the trustees’ annual report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the statement of trustees’ responsibilities set out in the trustees’ annual report, the trustees (who are also the directors of the charitable company for the purposes of company law) are

26

Endometriosis UK Independent Auditor’s Report for year ended 31 March 2023

responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below.

Capability of the audit in detecting irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and noncompliance with laws and regulations, our procedures included the following:

• We enquired of management, and the audit and risk committee, which included obtaining and reviewing supporting documentation, concerning the charity’s policies and procedures relating to:

• Identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance;

• Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud;

• The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.

• We inspected the minutes of meetings of those charged with governance.

• We obtained an understanding of the legal and regulatory framework that the charity operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the charity from our professional and sector experience.

• We communicated applicable laws and regulations throughout the audit team and remained alert to any indications of non-compliance throughout the audit.

27

Endometriosis UK Independent Auditor’s Report for year ended 31 March 2023

• We reviewed any reports made to regulators.

• We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations.

• We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud.

• In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities . This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company's members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Fleur Holden (Senior statutory auditor)

Date: 11 October 2023

for and on behalf of Sayer Vincent LLP, Statutory Auditor Invicta House, 108-114 Golden Lane, LONDON, EC1Y 0TL

Sayer Vincent LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006

28

Endometriosis UK

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2023

For theyear ended 31 March 2023
Note Income from: 2 Income from charitable activities 3 4 5 5 5 5 6 Reconciliation of funds: Total funds carried forward Net movement in funds Total funds brought forward Net income for the year Total expenditure Information services Research Helpline and support services Grants and donations Other trading activities Charitable activities Interest Other Total income Expenditure on: Raising funds	Unrestricted £ 299,811 - 392,558 6,253 6,437	Restricted £ - 189,511 - - -	2023 Total £ 299,811 189,511 392,558 6,253 6,437	Unrestricted £ 396,101 - 383,372 127 9,694	Restricted £ - 79,576 - - -	2022 Total £ 396,101 79,576 383,372 127 9,694
	705,059	189,511	894,570	789,294	79,576	868,870
	171,020 278,736 168,602 25,056	- 144,108 - -	171,020 422,844 168,602 25,056	125,707 267,714 132,398 15,008	- 39,613 - -	125,707 307,327 132,398 15,008
	643,413	144,108	787,521	540,827	39,613	580,440
	61,646	45,403	107,049	248,467	39,963	288,430
	61,646 1,139,959	45,403 51,763	107,049 1,191,722	248,467 891,492	39,963 11,800	288,430 903,292
	1,201,605	97,166	1,298,771	1,139,959	51,763	1,191,722

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 15a to the financial statements.

29

Endometriosis UK

Company no. 02912853

Balance sheet

As at 31 March 2023

As at 31 March 2023 Balance sheet	As at 31 March 2023 Balance sheet	As at 31 March 2023 Balance sheet	Company no. 02912853	Company no. 02912853
Note £ £ Fixed assets: 12 38,013 38,013 Current assets: 13 76,092 1,236,131 1,312,223 Liabilities: 14 (51,465) 1,260,758 1,298,771 1,298,771 16a 97,166 336,000 865,605 Total unrestricted funds 1,201,605 1,298,771 Total assets less current liabilities Debtors Restricted funds Unrestricted funds: Designated funds The funds of the charity: Creditors: amounts falling due within one year Net current assets Total net assets Cash at bank and in hand Tangible assets 2023 General reserve Total charity funds			£ £ 17,782 17,782 114,576 1,093,329 1,207,905 (33,965) 1,173,940 1,191,722 1,191,722 51,763 216,000 923,959 1,139,959 1,191,722 2022
		38,013 1,260,758		17,782 1,173,940
	1,312,223 (51,465)		1,207,905 (33,965)
	336,000 865,605		216,000 923,959
		1,298,771		1,191,722
		1,298,771		1,191,722
		97,166 1,201,605		51,763 1,139,959
		1,298,771		1,191,722

Approved by the trustees on 11th September 2023 and signed on their behalf by

Liz Campbell Director

Tracey Hammonds Director

30

Endometriosis UK

Statement of cash flows

For the year ended 31 March 2023

For the year ended 31 March 2023
Cash flows from operating activities Net income for the reporting period (as per the statement of financial activities) Depreciation charges Decrease/(Increase) in debtors Increase/(Decrease) in creditors Net cash provided by operating activities Cash and cash equivalents at the end of the year Change in cash and cash equivalents in the year Cash and cash equivalents at the beginning of the year Net cash used in investing activities Cash flows from investing activities: Purchase of property, plant and equipment	£ £ 107,049 7,656 38,484 17,500 170,689 (27,887) (27,887) 142,802 1,093,329 1,236,131 2023		£ £ 288,430 3,914 (18,632) 13,726 287,438 (12,513) (12,513) 274,925 818,404 1,093,329 2022
		170,689 (27,887)		287,438 (12,513)
		142,802 1,093,329		274,925 818,404
		1,236,131		1,093,329

31

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

1 Accounting policies

a) Statutory information

Endometriosis UK is a charitable company limited by guarantee and is incorporated in the UK.

The registered office address is 10-18 Union Street, London, SE1 1SZ.

b) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP FRS 102), The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

In accordance with the Charities SORP, the parent charity does not prepare consolidated financial statements on the basis that the annual gross income of the group does not exceed £1million.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

In applying the financial reporting framework, the trustees have made a number of subjective judgements, for example in respect of significant accounting estimates. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The nature of the estimation means the actual outcomes could differ from those estimates. Any significant estimates and judgements affecting these financial statements are detailed within the relevant accounting policy below.

c) Public benefit entity

The charity meets the definition of a public benefit entity under FRS 102.

d) Going concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern. Following the Covid19 pandemic and with concerns about the cost of living crisis, the trustees reviewed income and expenditure and undertook a risk analysis, resulting in recasting the budget to reduce expenditure, and looking to identify and maximise income opportunities. Expenditure was managed carefully through the year, and a focus on developing new income sources has resulted in a strong income level for the year.

32

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

1 Accounting policies (continued)

e) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably.

Income from government and other grants, whether ‘capital’ grants or ‘revenue’ grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor’s intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is a treated as a contingent asset and disclosed if material.

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met.

f) Donations of gifts, services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item or received the service, any conditions associated with the donation have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), volunteer time is not recognised so refer to the trustees’ annual report for more information about their contribution.

On receipt, donated gifts, professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

g) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

• h) Fund accounting

Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

33

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

• 1 Accounting policies (continued)

• i) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

• Costs of raising funds relate to the costs incurred by the charity in inducing third parties to make voluntary contributions to it, as well as the cost of any activities with a fundraising purpose

• Expenditure on charitable activities includes the costs of delivering services undertaken to further the purposes of the charity and their associated support costs, to include:

• Helpline and support services - providing services for the relief of endometriosis

• Information services - relating to advancing the education of those with the disease, the general public and health professionals regarding endometriosis

• Research - activities to support research into endometriosis to improve understanding, treatment and management of the disease.

• Other expenditure represents those items not falling into any other heading

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

• j) Allocation of support costs

• Resources expended are allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function, is apportioned on the following basis which are an estimate, based on staff time, of the amount attributable to each activity.

Where information about the aims, objectives and projects of the charity is provided to potential beneficiaries, the costs associated with this publicity are allocated to charitable expenditure.

Where such information about the aims, objectives and projects of the charity is also provided to potential donors, activity costs are apportioned between fundraising and charitable activities on the basis of area of literature occupied by each activity.

		2023	2022
	Raising funds	17%	19%
	Helpline & Support Services	55%	60%
	Information Services	20%	14%
	Research	8%	7%

Governance costs are the costs associated with the governance arrangements of the charity. These costs are associated with constitutional and statutory requirements and include any costs associated with the strategic management of the charity’s activities.

k) Operating leases

Rental charges are charged on a straight line basis over the term of the lease.

34

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

1 Accounting policies (continued)

• l) Tangible fixed assets

• Items of equipment are capitalised where the purchase price exceeds £200. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

 Office equipment

4 years

m) Debtors

Trade and other debtors are recognised at the settlement amount due

• n) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

• o) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

p) Pensions

The charity contributes to workplace pension schemes for its employees. Contributions are charged to the Statement of Financial Activities in the period to which they relate.

35

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

• 2 Income from grants and donations

Income from grants and donations
Endometriosis UK Trading Ltd Other donations Legacy donations Gift In Kind	Unrestricted £ (8,650) 306,961 - 1,500	£ - - - - Restricted	2023 Total £ (8,650) 306,961 - 1,500	Unrestricted £ 26,717 340,428 28,956 -	£ - - - - Restricted	2022 Total £ 26,717 340,428 28,956 -
	299,811	-	299,811	396,101	-	396,101

Repayment of excess/(distribution to) the parent charity under Gift Aid

• 3 Income from charitable activites

Income from charitable activites
Alliance - Scottish Grant Lottery Community Funding - Scotland Lottery Community Funding - Wales Scottish Government Intuitive Grant Access Group Foundation Grant Sense Foundation Grant DHSC Grant Blackbaud Grant	Unrestricted £ - - - - - - - - -	£ 29,999 34,081 30,418 30,000 9,900 17,250 32,863 5,000 Restricted	2023 Total £ 29,999 34,081 30,418 30,000 9,900 17,250 32,863 5,000	Unrestricted £ - - - - - - - - -	£ 30,000 34,576 - 15,000 - - - - - Restricted	2022 Total £ 30,000 34,576 15,000
	-	189,511	189,511	-	79,576	79,576

Income received from Endometriosis UK Trading Ltd is the distribution of profits under gift aid.

4 Income from other trading activities

Income from other trading activities
Challenge events Membership fees Other fundraising activities	Unrestricted £ 218,963 22,213 151,382	£ - - - Restricted	2023 Total £ 218,963 22,213 151,382	Unrestricted £ 193,195 27,624 162,553	£ - - - Restricted	2022 Total £ 193,195 27,624 162,553
	392,558	-	392,558	383,372	-	383,372

Other fundraising activities represent members and supporters raising funds on behalf of the charity.

36

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

5a Analysis of expenditure (current year)

Analysis of expenditure (current	year)
Staff costs (Note 7) Information Membership EFE Fundraising & Challenge Events Office costs Premises costs Professional Fees Helpline & Volunteer Expenses Other costs Support costs Governance costs Total expenditure 2023 Total expenditure 2022	Raising funds £ 78,338 - - 48,545 13,585 - - - 2,552	Charitable activities			Governance costs £ 14,271 - - - 3,176 - 7,850 - 2,328	Supports Costs £ 30,872 - - - 18,578 40,522 40,577 - 2,824	2023 Total £ 473,470 27,883 385 48,545 120,477 40,522 48,427 17,556 10,256	2022 Total £ 321,004 42,584 231 29,833 108,439 29,201 35,413 8,614 5,121
		Helpline and support services £ 251,399 - 385 - 62,578 - - 17,556 2,552	Information services £ 89,657 27,883 - - 18,687 - - - -	Research £ 8,933 - - - 3,873 - - - -
	143,020 23,195 4,804	334,470 73,210 15,164	136,227 26,820 5,555	12,806 10,148 2,102	27,625 - (27,625)	133,373 (133,373) -	787,521 - -	580,440 - -
	171,020	422,844	168,602	25,056	-	-	787,521	580,440
	125,707	307,327	132,398	15,008	-	-

37

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

5b Analysis of expenditure (prior year)

Staff costs (Note 7) Information Membership EFE Fundraising & Challenge Events Office costs Premises costs Professional Fees Helpline & Volunteer Expenses Other costs Support costs Governance costs Total expenditure 2022	Raising funds £ 58,469 - - 29,833 9,038 - - - 1,416	Charitable activities	Charitable activities	Charitable activities	Governance costs £ 9,902 - - - 396 - - - 855	Supports Costs £ 42,505 - - - 21,677 29,201 35,413 - 1,545	2022 Total £ 321,004 42,584 231 29,833 108,439 29,201 35,413 8,614 5,121
		Helpline and support services £ 160,863 - 231 - 52,091 - - 8,614 1,305	Information services £ 44,484 42,584 - - 25,117 - - -	Research £ 4,781 - - - 120 - - - -
	98,756 24,827 2,124	223,104 77,584 6,639	112,185 18,620 1,593	4,901 9,310 797	11,153 - (11,153)	130,341 (130,341) -	580,440 - -
	125,707	307,327	132,398	15,008	-	-	580,440

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

• 6 Net income for the year

This is stated after charging / (crediting):

This is stated after charging / (crediting):
	2023	2022
	£	£
Depreciation	7,656	3,914
Operating lease rentals payable:
Property	30,174	22,984
Other	886	1,328
Auditor's remuneration (excluding VAT):
Audit	7,850	6,825
Other services	990	2,095

• 7 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

Staff costs were as follows:

Staff costs were as follows:
Salaries and wages Social security costs Employer’s contribution to defined contribution pension schemes	2023 £ 425,256 37,541 10,673	2022 £ 292,155 22,965 5,884
	473,470	321,004

No employee earned more than £60,000 during the year (2022: nil).

The total employee benefits (including pension contributions and employer's national insurance) of the key management personnel were £50,384 (2022: £45,768).

The charity trustees were neither paid nor received any other benefits from employment with the charity in the year (2022: £nil). No charity trustee received payment for professional or other services supplied to the charity (2022: £nil).

Trustee expenses represents the payment or reimbursement of travel and subsistence costs totalling £88 (2022: £62) incurred by one (2023: 1) member relating to attendance at meetings of the trustees.

39

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

8 Staff numbers

The average number of employees (head count based on number of staff employed) during the year was 14.5 (2022: 13).

13 employees worked full time, with 9 employees working part time. The CEO is part time, 3 or 4 days per week.

Staff are split across the activities of the charity as follows (full time equivalent basis):

Staff are split across the activities of the charity as follows (full time equivalent basis):
Raising funds Information services Helpline and support services Research Governance	2023 No. 3.2 10.1 3.7 1.4 0.6	2022 No. 2.4 7.5 1.8 0.9 0.4
	19.0	13.0

9 Related party transactions

Endometriosis UK received donations totalling £320 (2022: £9,511) from 11 trustees (2022: 11). The trustees receive no benefit from the donations made to the charity.

During the financial year part of consultancy services totalling £0 (2022: £1200.00) were provided by the sister of one of the Endometriosis UK trustees, Andrew Glyde.

40

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

10 Subsidiary undertaking

Endometriosis UK Trading Limited was incorporated in the UK as a wholly owned subsidiary of Endometriosis UK on 2 June 2006 (Company No: 05836007), with an issued share capital of £1. The company started trading in the previous financial year.

A summary of the results of the subsidiary is shown below:

previous financial year. A summary of the results of the subsidiary is shown below:
Total retained earnings brought forward Total comprehensive income Distribution under Gift Aid to parent charity Total retained earnings carried forward Turnover Total comprehensive income Retained earnings The aggregate of the assets, liabilities and reserves was: Assets Liabilities Reserves Taxation on profit on ordinary activities Gross profit/(loss) Administrative expenses Profit/(loss) on ordinary activities before interest and taxation	2023 £ 7	2022 £ 11,849
	7 (8,142)	11,849 (896)
	(8,135) -	10,953 -
	(8,135)	10,953
	(4,754) (8,135) 15,764	11,010 10,953 (26,717)
	2,875	(4,754)
	2,875 -	3,167 (7,921)
	2,875	(4,754)

• 11 Taxation

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

41

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

For the year ended 31 March 2023
12 13 14 Tangible fixed assets At the end of the year Additions in year Depreciation At the end of the year At the start of the year Charge for the year At the end of the year At the start of the year Cost Net book value Prepayments Accrued income At the start of the year All of the above assets are used for charitable purposes. Debtors Amounts due from subsidiary Accruals Taxation and social security Amounts due to subsidiary Creditors: amounts falling due within one year Other creditors Other debtors	Office equipment £ 28,571 27,887	Total £ 28,571 27,887
	56,458	56,458
	10,789 7,656	10,789 7,656
	18,445	18,445
	38,013	38,013
	17,782	17,782
	2023 £ 9,975 53,502 12,615 -	2022 £ 16,550 90,009 2,436 5,581
	76,092	114,576
	2023 £ 17,775 17,186 15,121 1,383	2022 £ 9,340 17,955 6,670 -
	51,465	33,965

42

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

15a Analysis of net assets between funds (current year)

Analysis of net assets between funds (current year)
Net assets at 31 March 2023 Tangible fixed assets Net current assets	General unrestricted £ 38,013 1,163,592	Restricted £ - 97,166	Total funds £ 38,013 1,260,758
	1,201,605	97,166	1,298,771

15b Analysis of net assets between funds (prior year) Net assets at 31 March 2022 Tangible fixed assets Net current assets	General unrestricted £ 17,782 1,122,177	Restricted £ - 51,763	Total funds £ 17,782 1,173,940
	1,139,959	51,763	1,191,722

43

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

16a Movements in funds (current year)

Movements in funds (current year)
Lottery Community Funding - Wales Intuitive Grant Access Group Foundation Grant Sense Foundation Grant DHSC Grant Blackbaud Grant Total restricted funds Total designated funds General funds Designated funds: Webchat and Helpline expansion Restricted funds: Takeda Lottery Community Funding - Scotland Additional Scottish Project Diversity & Inclusion activities Alliance - Scottish Grant Unrestricted funds: Total funds Total unrestricted funds	At 1 April 2022 £ 10,050 27,106 - 14,607 - - - - -	Income and gains £ - 34,081 30,418 29,999 30,000 9,900 17,250 32,863 5,000	Expenditure and losses £ (10,050) (38,076) (424) (34,635) (23,200) (4,263) - (32,863) (597)	Transfers £ - - - - - - - - -	At 31 March 2023 £ - 23,111 29,994 9,971 6,800 5,637 17,250 - 4,403
	51,763	189,511	(144,108)	-	97,166
	140,000 40,000 36,000	- - -	- - -	- - 120,000	140,000 40,000 156,000
	216,000	-	-	120,000	336,000
	923,959	705,059	(643,413)	(120,000)	865,605
	1,139,959	705,059	(643,413)	-	1,201,605
	1,191,722	894,570	(787,521)	-	1,298,771

The narrative to explain the purpose of each fund is given at the foot of the note below.

44

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

16b Movements in funds (prior year)

Movements in funds (prior year)
Total restricted funds Total designated funds General funds Designated funds: Restricted funds: Lottery Community Fund Takeda Alliance - Scottish Grant Webchat and Helpline expansion Additional Scottish Project Scottish Government Unrestricted funds: Total unrestricted funds Diversity & Inclusion activities Total funds	At 31 March 2021 £ 11,800 - - -	Income and gains £ - 34,576 30,000 15,000	Expenditure and losses £ (1,750) (7,470) (15,393) (15,000)	Transfers £ - - - -	At 31 March 2022 £ 10,050 27,106 14,607 -
	11,800	79,576	(39,613)	-	51,763
	- - - -	- - - -	- - - -	- 140,000 40,000 36,000	- 140,000 40,000 36,000
	-	-	-	216,000	216,000
	891,492	789,294	(540,827)	(216,000)	923,959
	891,492	789,294	(540,827)	-	1,139,959
	903,292	868,870	(580,440)	-	1,191,722

45

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

Purpose of restricted funds

Restricted funds represent donations and grants restricted for use on particular areas of the charity's work.

Takeda

Our funding from Takeda has been used to improve online information for diagnosis and treatments Alliance Project

The Health and Social Care Alliance in Scotland provided a grant to support

• Launching new Support Groups in Scotland

• Developing information materials

• Supporting the resumption of face-to-face Support Group meetings

• Delivering volunteer training

Lottery Community Funding - Scotland

The National Lottery Community Fund provided a grant to support

• Expanding and strengthening Support Groups in Scotland

• Increasing the awareness and availability of our Helpline, WebChat and information resources

• Appointing a Scotland-based staff member to deliver the above

Intuitive Grant

Intuitive Grant developing information resources on endometriosis surgery

• Developing video content with specilialist surgeons and patients

• Producing online and printable leaflets to include RAS and laparoscopy.

Lottery Community Funding - Wales

The National Lottery Community Fund provided a grant to support

• Expanding and strengthening Support Groups in Wales

• Increasing the awareness and availability of our Helpline, WebChat and information resources

• Appointing a Wales based staff member to deliver the above

DHSC Grant

DHSC Grant to develop a workplace menstrual wellbeing programme

• Developing and providing information and guidance on a range of menstrual conditions to SME's

• Providing SME's with targeted information events, webinars, resources and downloadable information

The Access Foundation Grant

Funding for web Chat, Helpline and Information

• Funding towards the develoment of information

• Funding towards the costs of the helpline and web chat

SENSE Foundation Brussels Grant

Support and Information project

• Recruting and training helpline and web chat volunteers

• Reviewing and developing information

• Increasing helpline and webchat provision

Blackbaud Grant

Funds towards the Endometriosis UK Helpline and webchat

 Funds towards the Endometriosis UK Helpline and webchat

46

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2023

16 Movements in funds (continued)

Purpose of designated funds

Webchat and Helpline expansion

To fund the ongoing support, development and expansion for a webchat and helpline services over the three years.

Additional Scottish Project

This is in addition to the grant funding received allowing us to undertake additional activities in Scotland and will be spent over the next three years.

Additional Diversity and Inclusion activities

We had identified that we had less reach within certain communities, notably those from black, Asian and minority ethnic and LGBTQ+ community. Additional funding has been allocated, to increase capacity in this area, undertake research and deliver improved reach over the next three years.

17 Operating lease commitments payable as a lessee

The charity's total future minimum lease payments under non-cancellable operating leases is as follows for each of the following periods

the following periods
Less than one year - Mutual 3 month break clause	2023 2022 £ £ 7,508 6,175 7,508 6,175 Property		2023 2022 £ £ - - - - Other
	7,508	6,175	-	-

• 18 Legal status of the charity

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

47